Analytical Data
-
Gene name
HLA-A*02:01&B2M&P53 R175H(HMTEVVRHC) Tetramer
- Application
-
Alternative Names
MHC; HLA-A; P53; TP53; Antigen NY-CO-13; BCC7; FLJ92943; LFS1; TRP53
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&HMTEVVRHC
-
Molecular Weight
260-265 kDa, based on SDS-PAGE under non reducing conditions,.
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01/B2M/P53 R175H (HMTEVVRHC) tetramer protein is a crucial tool for studying cancer immunology, particularly in the context of tumor-associated antigens and T cell responses. The P53 gene, known as a tumor suppressor, is frequently mutated in various cancers, with the R175H mutation being one of the most common alterations. This mutation leads to an altered peptide that can be presented by the HLA-A*02:01 molecule, a highly prevalent human leukocyte antigen that plays a key role in immune recognition. The incorporation of beta-2-microglobulin (B2M) is essential for the stable expression of the HLA-A*02:01 molecule. By creating a tetramer comprising HLA-A*02:01, B2M, and the P53 R175H peptide, researchers can effectively identify and isolate T cells that specifically recognize this mutant peptide, providing insights into T cell immunology in cancer. The tetramer's application can foster the development of immunotherapeutic strategies by elucidating the mechanisms by which the immune system recognizes and targets tumor cells harboring such mutations. This research is instrumental in advancing our understanding of cancer immunotherapy, paving the way for personalized treatment approaches that leverage the body’s immune defenses against tumors.
